FDA Approves Generic Version of PhosLo Gelcaps

Perrigo Co. June 6 announced that the Food and Drug Administration has approved its generic version of Fresenius Medical Care Holdings Inc.'s PhosLo Gelcaps (calcium acetate).

The product is indicated for hyperphosphatemia in patients with end-stage kidney disease who are on dialysis, the company said.

Perrigo, which is based in Allegan, Mich., said it was in patent litigation over this product with the branded company and the litigation was settled in late 2011. The terms are confidential, the company said.